Aster DM just got CCI’s green light for a major share acquisition and merger. What does this mean for the future? Read all about it!

Aster DM Healthcare has received approval from the Competition Commission of India (CCI) for a planned transaction. This approval, dated April 15, 2025, covers two main steps:

1. Acquisition of Shares: Aster DM will acquire 1,90,46,028 shares from BCP Asia II TopCo IV (BCP) and Centella Mauritius Holdings (Centella), who are the shareholders of Quality Care India Limited (QCIL). Instead of paying cash for these shares, Aster DM will issue 1,86,07,969 new shares to BCP and Centella as part of a share swap.

   Read More: PB Fintech Gets RBI Approval to Start Online Payment Aggregator Services

2. Merger of Companies: Aster DM will merge with QCIL through a scheme under the Companies Act, 2013. This means QCIL will combine with Aster DM, and its shareholders (except for Aster DM itself) will receive Aster DM shares based on a set exchange ratio. This merger will be treated as a continuation of QCIL’s business, and Aster DM will take over QCIL’s operations.

These two steps—share swap and merger—make up the proposed transactions that Aster DM plans to complete with CCI’s approval.